Loading organizations...

§ Private Profile · Houston, TX, USA
AI enabling digital urine diagnostics in the home
Starling has raised $628.8M across 5 funding rounds.
Key people at Starling.
Starling was founded in 2019 by Hannah McKenney (Founder) and Drew Hendricks (Founder).
Starling has raised $628.8M in total across 5 funding rounds.
Starling is building a urine diagnostic remote patient monitoring platform that seamlessly integrates into anyone's bathroom routine. By detecting early changes in a patient's urine using our toilet indwelling mass spectroscopy device, our platform is aiming to prevent hospitalizations from numerous conditions like recurrent UTIs, BPH exacerbations, or diabetes. We do this while creating significant new annual revenues for our clinician partners from remote patient monitoring reimbursements without requiring any significant changes in a staff's day to day schedule.
Key people at Starling.
Starling has raised $628.8M across 5 funding rounds. Most recently, it raised $3.4M Starling Medical - Seed in January 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 27, 2023 | $3.4M Seed | Rebel Fund | Capital Factory, Centauri Fund, Gaingels, Innospark Ventures, Magic Fund, Praxis Spinal Cord Institute, Y Combinator | Announced |
| Apr 19, 2021 | $69.3M Venture Round | James Hayward | — | Announced |
| Mar 8, 2021 | $376.4M Series D | Fidelity Management & Research Company | Millennium Management, Qatar Investment Authority, RPMI Railpen | Announced |
| May 29, 2020 | $49.3M Venture Round | JTC, Merian Chrysalis | — | Announced |
| Feb 22, 2019 | $130.4M Grant | Banking Competition Remedies | — | Announced |
Starling Medical is a healthcare technology company developing an AI-enabled digital urine diagnostic platform designed for at-home use. Their flagship product, StarStream (also called UrinDx), is a urine monitoring device that integrates seamlessly into a user’s bathroom routine by attaching to the toilet. It uses AI and spectroscopy sensors to analyze urine in real time, enabling early detection of conditions such as recurrent urinary tract infections (rUTIs), benign prostatic hyperplasia (BPH) exacerbations, and diabetes complications. This remote patient monitoring platform serves patients with chronic urological conditions and provides clinicians with actionable health insights while generating new revenue streams through remote monitoring reimbursements without disrupting clinical workflows[1][2][5].
The company addresses a significant healthcare challenge by enabling continuous, non-invasive monitoring that can prevent hospitalizations and reduce repeat clinic visits. Starling’s solution empowers patients with personalized health data delivered via a smartphone app and supports clinicians with timely alerts and care coordination. The company has demonstrated growth momentum through clinical validation, seed funding rounds, and enterprise partnerships, including deployment with a large urology practice managing 200,000 patients, projecting substantial recurring revenue potential[2][3].
Starling Medical was founded in 2019 in Houston, Texas, by Hannah McKenney, Alex Arevalos, and Drew Hendricks. The founders bring a blend of clinical, medical device, and digital health expertise. Hannah McKenney’s background in hospital and industry settings shaped the company’s focus on user-centered design and accessibility in medical technology. The idea originated from the need to improve monitoring for patients with neurological bladder dysfunction and recurrent urinary conditions, initially developing a catheter-based device to track urine in the bladder using AI and spectroscopy[1][2][3].
Early traction included clinical studies in partnership with Stanford University validating their predictive models, and a successful seed funding round led by Rebel Fund and other investors. The company evolved from catheter-based monitoring to a non-invasive toilet-attached device, StarStream, which better fits into daily life and broadens patient adoption. A pivotal moment was securing a large enterprise customer in Texas for deployment in 2023, marking a transition from development to commercial scale[2][3].
Starling Medical rides the convergence of several important trends:
The timing is favorable due to reimbursement frameworks supporting RPM, increasing clinician interest in scalable digital tools, and growing patient acceptance of home diagnostics. Starling’s innovation influences the ecosystem by demonstrating how AI and non-invasive sensing can transform routine health monitoring and chronic care management[1][2][6].
Starling Medical is positioned to expand its footprint in urology and chronic disease management by scaling enterprise deployments and refining its AI algorithms. Future trends shaping its journey include broader adoption of AI-driven diagnostics, integration with telehealth platforms, and potential expansion into other biomarkers and conditions detectable via urine analysis.
As reimbursement policies evolve and healthcare systems emphasize remote care, Starling’s platform could become a standard tool for early detection and prevention, reducing healthcare costs and improving patient outcomes. Continued clinical validation and user experience enhancements will be critical to sustaining growth and influence.
In summary, Starling Medical exemplifies the next generation of digital health innovation by transforming a simple, everyday activity—using the bathroom—into a powerful diagnostic and monitoring opportunity, aligning with the future of personalized, preventive healthcare[1][2][3][5][6].
Starling was founded in 2019 by Hannah McKenney (Founder) and Drew Hendricks (Founder).
Starling has raised $628.8M in total across 5 funding rounds.
Starling's investors include Rebel Fund, Capital Factory, Centauri Fund, Gaingels, Innospark Ventures, Magic Fund, Praxis Spinal Cord Institute, Y Combinator, James Hayward, Fidelity Management & Research Company, Millennium Management, Qatar Investment Authority.